Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1984 May;73(5):1304–1311. doi: 10.1172/JCI111333

Metabolic clearance and plasma disappearance rates of human pancreatic tumor growth hormone releasing factor in man.

L A Frohman, J L Thominet, C B Webb, M L Vance, H Uderman, J Rivier, W Vale, M O Thorner
PMCID: PMC425152  PMID: 6425363

Abstract

The metabolic clearance rate (MCR) and plasma disappearance rate (t1/2) of human pancreatic tumor growth hormone releasing factor [hpGRF(1-40)] was determined in normal adult male subjects by single injection and constant infusion techniques. Single injections of 1, 3.3, and 10 micrograms/kg hpGRF(1-40) were administered intravenously, plasma immunoreactive (IR) GRF levels were measured during the subsequent 180 min, and biexponential curve analysis was performed. Graded, dose-constant infusions of hpGRF(1-40) at rates of 1, 3.3, 10, and 33 ng/kg per min were administered and the MCR was calculated from measurement of steady state plasma IR-GRF levels at each infusion rate. The postinfusion disappearance rate was determined by linear regression analysis of plasma IR-GRF levels during the 120-min period after cessation of the infusion. The calculated MCR during the single injection study was 194 +/- 17.5 liters/m2 per d and was not significantly different from the calculated value during the constant infusion study (202 +/- 16 liters/m2 per d). The disappearance rate during the single injection study was subdivided into two linear phases: an initial equilibration phase (7.6 +/- 1.2 min) and a subsequent elimination phase (51.8 +/- 5.4 min). The latter was similar to the linear disappearance rate observed (41.3 +/- 3.0 min) after cessation of the constant infusion. The chromatographic and biologic characteristics of plasma IR-GRF, 30 min after injection, were similar to those of synthetic hpGRF(1-40). The results have been discussed in relation to the MCR of other hypothalamic hormones and have been used to extrapolate secretion rates of GRF in patients with ectopic GRF production.

Full text

PDF
1304

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berelowitz M., LeRoith D., von Schenk H., Newgard C., Szabo M., Frohman L. A., Shiloach J., Roth J. Somatostatin-like immunoactivity and biological activity is present in Tetrahymena pyriformis, a ciliated protozoan. Endocrinology. 1982 Jun;110(6):1939–1944. doi: 10.1210/endo-110-6-1939. [DOI] [PubMed] [Google Scholar]
  2. Bloch B., Brazeau P., Ling N., Bohlen P., Esch F., Wehrenberg W. B., Benoit R., Bloom F., Guillemin R. Immunohistochemical detection of growth hormone-releasing factor in brain. Nature. 1983 Feb 17;301(5901):607–608. doi: 10.1038/301607a0. [DOI] [PubMed] [Google Scholar]
  3. Esch F. S., Böhlen P., Ling N. C., Brazeau P. E., Wehrenberg W. B., Thorner M. O., Cronin M. J., Guillemin R. Characterization of a 40 residue peptide from a human pancreatic tumor with growth hormone releasing activity. Biochem Biophys Res Commun. 1982 Nov 16;109(1):152–158. doi: 10.1016/0006-291x(82)91578-9. [DOI] [PubMed] [Google Scholar]
  4. Frohman L. A., Bernardis L. L. Growth hormone and insulin levels in weanling rats with ventromedial hypothalamic lesions. Endocrinology. 1968 Jun;82(6):1125–1132. doi: 10.1210/endo-82-6-1125. [DOI] [PubMed] [Google Scholar]
  5. Frohman L. A., Szabo M., Berelowitz M., Stachura M. E. Partial purification and characterization of a peptide with growth hormone-releasing activity from extrapituitary tumors in patients with acromegaly. J Clin Invest. 1980 Jan;65(1):43–54. doi: 10.1172/JCI109658. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. GREENWOOD F. C., HUNTER W. M., GLOVER J. S. THE PREPARATION OF I-131-LABELLED HUMAN GROWTH HORMONE OF HIGH SPECIFIC RADIOACTIVITY. Biochem J. 1963 Oct;89:114–123. doi: 10.1042/bj0890114. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Genuth S. M. Metabolic clearance of insulin in man. Diabetes. 1972 Oct;21(10):1003–1012. doi: 10.2337/diab.21.10.1003. [DOI] [PubMed] [Google Scholar]
  8. Guillemin R., Brazeau P., Böhlen P., Esch F., Ling N., Wehrenberg W. B. Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. Science. 1982 Nov 5;218(4572):585–587. doi: 10.1126/science.6812220. [DOI] [PubMed] [Google Scholar]
  9. Kohler P. O., Ross G. T., Odell W. D. Metabolic clearance and production rates of human luteinizing hormone in pre- and postmenopausal women. J Clin Invest. 1968 Jan;47(1):38–47. doi: 10.1172/JCI105713. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Leppaluoto J., Virkkunen P., Lybeck H. Elimination of TRH in man. J Clin Endocrinol Metab. 1972 Sep;35(3):477–478. doi: 10.1210/jcem-35-3-477. [DOI] [PubMed] [Google Scholar]
  11. Matsuyama H., Ruhmann-Wennhold A., Johnson L. R., Nelson D. H. Disappearance rates of exogenous and endogenous ACTH from rat plasma measured by bioassay and radioimmunoassay. Metabolism. 1972 Jan;21(1):30–35. doi: 10.1016/0026-0495(72)90017-0. [DOI] [PubMed] [Google Scholar]
  12. Nicholson W. E., DeCherney G. S., Jackson R. V., DeBold C. R., Uderman H., Alexander A. N., Rivier J., Vale W., Orth D. N. Plasma distribution, disappearance half-time, metabolic clearance rate, and degradation of synthetic ovine corticotropin-releasing factor in man. J Clin Endocrinol Metab. 1983 Dec;57(6):1263–1269. doi: 10.1210/jcem-57-6-1263. [DOI] [PubMed] [Google Scholar]
  13. Redding T. W., Kastin A. J., Gonzales-Barcena D., Coy D. H., Coy E. J., Schalch D. S., Schally A. V. The half-life, metabolism and excretion of tritiated luteinizing hormone-releasing hormone (LH-RH) in man. J Clin Endocrinol Metab. 1973 Oct;37(4):626–631. doi: 10.1210/jcem-37-4-626. [DOI] [PubMed] [Google Scholar]
  14. Rick J., Szabo M., Payne P., Kovathana N., Cannon J. G., Frohman L. A. Prolactin-suppressive effects of two aminotetralin analogs of dopamine: their use in the characterization of the pituitary dopamine receptor. Endocrinology. 1979 May;104(5):1234–1242. doi: 10.1210/endo-104-5-1234. [DOI] [PubMed] [Google Scholar]
  15. Rivier J., Spiess J., Thorner M., Vale W. Characterization of a growth hormone-releasing factor from a human pancreatic islet tumour. Nature. 1982 Nov 18;300(5889):276–278. doi: 10.1038/300276a0. [DOI] [PubMed] [Google Scholar]
  16. Saeed uz Zafar M., Mellinger R. C., Fine G., Szabo M., Frohman L. A. Acromegaly associated with a bronchial carcinoid tumor: evidence for ectopic production of growth hormone-releasing activity. J Clin Endocrinol Metab. 1979 Jan;48(1):66–71. doi: 10.1210/jcem-48-1-66. [DOI] [PubMed] [Google Scholar]
  17. Sheppard M., Shapiro B., Pimstone B., Kronheim S., Berelowitz M., Gregory M. Metabolic clearance and plasma half-disappearance time of exogenous somatostatin in man. J Clin Endocrinol Metab. 1979 Jan;48(1):50–53. doi: 10.1210/jcem-48-1-50. [DOI] [PubMed] [Google Scholar]
  18. Sherwin R. S., Kramer K. J., Tobin J. D., Insel P. A., Liljenquist J. E., Berman M., Andres R. A model of the kinetics of insulin in man. J Clin Invest. 1974 May;53(5):1481–1492. doi: 10.1172/JCI107697. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Spiess J., Rivier J., Thorner M., Vale W. Sequence analysis of a growth hormone releasing factor from a human pancreatic islet tumor. Biochemistry. 1982 Nov 23;21(24):6037–6040. doi: 10.1021/bi00267a002. [DOI] [PubMed] [Google Scholar]
  20. Spiess J., Rivier J., Vale W. Characterization of rat hypothalamic growth hormone-releasing factor. Nature. 1983 Jun 9;303(5917):532–535. doi: 10.1038/303532a0. [DOI] [PubMed] [Google Scholar]
  21. TAIT J. F., LITTLE B., TAIT S. A., FLOOD C. The metabolic clearance rate of aldosterone in pregnant and nonpregnant subjects estimated by both single-injection and constant-infusion methods. J Clin Invest. 1962 Dec;41:2093–2100. doi: 10.1172/JCI104667. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. TAIT J. F. REVIEW: THE USE OF ISOTOPIC STEROIDS FOR THE MEASUREMENT OF PRODUCTION RATES IN VIVO. J Clin Endocrinol Metab. 1963 Dec;23:1285–1297. doi: 10.1210/jcem-23-12-1285. [DOI] [PubMed] [Google Scholar]
  23. Thorner M. O., Perryman R. L., Cronin M. J., Rogol A. D., Draznin M., Johanson A., Vale W., Horvath E., Kovacs K. Somatotroph hyperplasia. Successful treatment of acromegaly by removal of a pancreatic islet tumor secreting a growth hormone-releasing factor. J Clin Invest. 1982 Nov;70(5):965–977. doi: 10.1172/JCI110708. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Thorner M. O., Rivier J., Spiess J., Borges J. L., Vance M. L., Bloom S. R., Rogol A. D., Cronin M. J., Kaiser D. L., Evans W. S. Human pancreatic growth-hormone-releasing factor selectively stimulates growth-hormone secretion in man. Lancet. 1983 Jan 1;1(8314-5):24–28. doi: 10.1016/s0140-6736(83)91563-5. [DOI] [PubMed] [Google Scholar]
  25. Vasquez B., Harris V., Unger R. H. Extraction of somatostatin from human plasma on octadecylsilyl silica. J Clin Endocrinol Metab. 1982 Oct;55(4):807–809. doi: 10.1210/jcem-55-4-807. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES